• Accepting Children: No
• Accepting New Patients: Yes

• Accepting Medicare: Yes
• Accepting Medicaid/DSHS: Yes

Payment Methods Accepted:

Medicare, Medicaid/DSHS, Bill Insurance, VISA, Master Card, Cash, Check, American Express, Discover Card, Money Order

Insurance Accepted:

Contact this office for accepted insurance plans.

Additional Information:

APPOINTMENTS:

Senior Investigator, Swedish Medical Center Cancer Institute
Professor of Medicine, University of Washington School of Medicine
Southwest Oncology Group, Principal Investigator for PSOC
Southwest Oncology Group, Chairman, Clinical Practices Committee
Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium (PSOC), President
The Marsha Rivkin Ovarian Cancer Research Center, Founder and Chairman of the Board

---

HONORS:

Association of Community Cancer Centers, Excellence in Research Award, 2000

---

PROFESSIONAL ASSOCIATIONS:

American Medical Association
American Society of Clinical Oncology
American Society of Hematology
Leukemia Group B, Affiliated Member through Walter Reed Institute

Personal Interests

Dr. Rivkin's professional involvement includes acting as: Professor of Clinical Oncology, University of Washington; President, Puget Sound Oncology Consortium; Principal Investigator, Southwest Oncology Group. In addition, Dr. Rivkin is the Founder and Chairman of the Board for the Marsha Rivkin Center for Ovarian Cancer Research. Dr. Rivkin founded the Center in honor of his late-wife Marsha in order to save lives and reduce suffering through improved treatment, early detection and prevention of ovarian cancer.

Medical School

University of Washington, WA

Residency

Internal Medicine: University of New Mexico; Hematology: University of New Mexico

Fellowship(s)

University of New Mexico and University of Texas at M.D. Anderson Hospital

Additional Information:

APPOINTMENTS:

Senior Investigator, Swedish Medical Center Cancer Institute
Professor of Medicine, University of Washington School of Medicine
Southwest Oncology Group, Principal Investigator for PSOC
Southwest Oncology Group, Chairman, Clinical Practices Committee
Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium (PSOC), President
The Marsha Rivkin Ovarian Cancer Research Center, Founder and Chairman of the Board

---

HONORS:

Association of Community Cancer Centers, Excellence in Research Award, 2000

---

PROFESSIONAL ASSOCIATIONS:

American Medical Association
American Society of Clinical Oncology
American Society of Hematology
Leukemia Group B, Affiliated Member through Walter Reed Institute

CLINICAL TRIALS:

Dr. Saul Rivkin is the lead investigator for the following clinical trials currently available at the Swedish Cancer Institute:

A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer

Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Phase Ib with Expansion of Patients at the MTD Study of Olaparib plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
________________________________________

PUBLICATIONS:

Chu DZ, Hussey MA, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer. 2011 Dec;10(4):310-6. Epub 2011 Jul 22

Phillip, PA, Benedetti J, Corless CL, Wong R, O’Reilly, EM, Atkins JN, Rivkin SE, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 2010 Aug 1;28(22): 3605-10. Epub 2010 Jul 6. PMID: 20606093

Rivkin SE, Muller C, Moon J, Iriarte D, Arthur J, Gerould H, Malmgren JA. A Phase I/II Study of Lapatinib plus Carboplatin and Paclitaxel in Stage III/IV Relapsed Ovarian Cancer. Clinical Ovarian Cancer 2009 Nov; v(2):112-117.

Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M. Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol. 2009 Aug; 114(2):206-9. Epub 2009 May 23. PMID: 19464730

Blumenthal D, Rankin CJ, Petersdorf S, Rushing E, Spence A, Berger MS, Harmon E, Rivkin SE, Livingston, R, Stelzer K, Cohn AL. C-2755-07 Version 2: External beam Irradiation and Cisplatin/BCNU Followed by BCNY for the treatment of High Grade Gliomas: A Phase II study. Southwest Oncology Group Trial. Cancer 2008 Aug 1; 113(3):559-65. PMID: 18521920

Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED; Southwest Oncology Group Trial 8733. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733. Cancer. 2008 May 15;112(10):2181-7. PMID: 18404692

Blumenthal D, Rankin CJ, Petersdorf S, Rushing E, Spence A, Berger MS, Harmon E, Rivkin SE, Livingston, R, Stelzer K, Cohn AL. C-2755-07 Version 2: External beam Irradiation and Cisplatin/BCNU Followed by BCNY for the treatment of High Grade Gliomas: A Phase II Southwest Oncology Group Trial. Cancer 2008

Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT. A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol. 2008 Feb;86(3):353-8. Epub 2007 Nov 16.PMID: 18175205

Rivkin SE, Moon J, Atwood MJ, Tennent N. Treatment Outcomes in Breast Cancer Patients with 4 or more Positive Lymph Nodes Evaluating Neoadjuvant to Adjuvant Therapy. Poster presented at San Antonio Breast Cancer Symposium, San Antonio, Texas USA Dec 2007

Garland LL, Rankiin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol, 2007 Jun 10; 25(17):2406-13. PMID: 17557954.

Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS. Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium. International Journal of Gynecologic Cancer 16(4):463–9, 2006.

Rivkin SE, Body JJ, Diel I, Bergstrom B. Long-term Safety of Intravenous Ibandronate (i.v.) by Bolus Injection or Infusion for up to 4 years in Metastatic Bone Disease: Results of an Open-Label Study. Poster Presented at the IVth Inertnational Conference on Cancer-Induced Bone Diseases, San Antonio, Texax USA December, 2003. Clinical Drug Investigation, March 2006

Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE and Osborne KC. Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil vs Cyclophosphamide, Doxorubicin, and Fluorouracil with and without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Inergroup Protocol INT-0102. Journal of Clinical Oncology, Vol. 23, No 33 Nov. 20, 2005

McCoy S; Macdonald J, Rivkin SE; Dakhil S, Lenz H; Abbruzzese J, Tanaka M. A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer: A Southwest Oncology Group Study.  Investigational New Drugs, August 2005

West HL; Crowley JJ; Vance RB; Franklin WA Livingston ; RB; Dakhil SR; Giguere JK; Rivkin SE; Kraut M; Chansky K; Gandara DR . A Southwest Oncology Group Study. Advanced Bronchioloalveolar Carcinoma: A Phase II Trial of Paclitaxel by 96-Hour Infusion (SWOG 9714): A Southwest Oncology Group Study. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2005 Jul; Vol. 16 (7), pp. 1076-80. Date of Electronic Publication: 2005 Apr 28

Poplin EA, Benedetti JK; Estes NC, Haller DG; Mayer RJ ; Goldberg RM, Weiss GR; Rivkin SE; Macdonald JS.A Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized Trial of Fluorouracil, Leucovorin, and Levamisole versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005 Mar 20; Vol. 23 (9), pp. 1819-25

Whitehead R P, McCoy S A, Rivkin SE, Gross H M, Conrad M E and Abbru J L. A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) in Patients with Advanced Pancreas Cancer: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 22

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr Jr. J, Rivkin SE, Schultes BC, Whiteside TL, Nicodemus CF. Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients with Advanced Ovarian Cancer. J Clin Oncol. 2004 Sep 1;22(17):3507-16

Sabbatini P, Aghajanian C, Dizon D, S Anderson, Dupont J, Brown , VJ, WA Peters, A Jacobs, A Mehdi, Rivkin SE, AJ Eisenfeld, D Spriggs. Phase II Study of CT-2103 in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. J Clin Oncol. 2004 Nov 15;22(22):4523-31

Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, and Fisher RI. A Phase 2 Trial of CHOP Chemotherapy Followed by Tositumonab/iodine I131 Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: A Southwest Oncology Group Protocol S9911. Blood Sept 2003, Vol 102 No 5

Chu DZJ, Chansky K, Alberts DS, Meyskens Jr. FL, Fenogilio-Preiser CM, Rivkin SE, Glenn MM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman SM. Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study. Annals of Surgical Oncology, 2003 Nov.10(8):870-875

Rivkin SE, Green, SJ, Lew, D, Costanzi, JJ,. Athens,JW Osborne, KC, Vaughn, CB, Martino, S. 20-year results of a Southwest Oncology Group study (SWOG 7436). Adjuvant Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil, Vincristine, and Prednisone Compared with Single-Agent-L- Phenylalanine Mustard for Patients with Operable Breast Carcinoma and Positive Axillary Lymph Nodes. Cancer 2003, vol 97, No. 1, pp 21-29

Klein C E, Tangen C M, Braun TJ, Hussain M H A, Peereboom D, Nichols C R, Rivkin SE, Dakhil RS, and Crawford ED. (A Southwest Oncology Group Study SWOG 9510) Evaluation of Topotecan in Hormone Refractory Prostate Cancer. Wiley InterScience 2002 Vol 52, pp 264-268

Ramsey S D, Moinpour C, Lovatto LC,. Crowley JJ, Grevstad PK, Presant CA, Rivkin SE, Kelly K, Grandara D. Economic Analysis of Vinorelbine Plus Cisplatin versus Paclitaxel plus Carboplatin for Advanced Non-Small Cell Lung Cancer. (A Southwest Oncology Group Study SWOG 9509) Journal of the National Cancer Institute Vol. 94, No.4 2002, pp 291-297

Dhodapkar MV. Jacobson JL, Gertz AM, Rivkin SE, Roodman GE, Tuscano JM, Shurafa M, RA Kyle, Crowley JJ and Barlogie B. Prognostic Factors and Response to Fludarabine Therapy in Patients with Waldstrom Macroglobulinemia: Results of United States Intergroup Trial (Southwest Oncology Group S9003) Blood 2001; 98:41-48

Macdonald SJ, Jacobson JL, Ketchel SJ, Weiss G, Taylor S, Mills G, Kuebler PJ, Rivkin SE, and Conrad M. A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339) Investigational New Drugs 2000, (18) 199 – 202

Patnaik A, Warner E, l Michael M, Egorin MJ, Moore, MJ, Siu LL, Fracasso PM, Rivkin SE, Kerr I, Litchman M and Oza AM. A Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin with Oral Valspodar in Patients with Advanced Solid Tumors.
Journal of Clinical Oncology Vol 18 No. 21, 2000: pp 3677-3689

Elias L, Lew D, Figlin RA, Flanigan RC, Thompson ME, Triozzi PL, Belt RJ, Wood DP Jr, Rivkin SE, David E. Infusional Interleukin-2 and 5-Fluorouracil with Subcutaneous interferon-alpha for the Treatment of Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Phase II Study. Cancer 2000 Aug 1;89(3):597-603

Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85(4):786-795.

Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: A Southwest Oncology Group study. Journal of Urology 1999 Jun;161(6):1823-5

Meyers FJ, Lew D, Lara PN Jr, Williamson S, Marshall E, Balcerzak SP, Rivkin SE, Samlowski W, Crawford ED. A Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124). Investigational New Drugs 1998-99;16(4):347-51

Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R, Klarnet J, Zuckerman N, Harrer G, McCloskey R, Gersh R, Goldberg R, Nichols W, Jacobs A, Weiden P, Montgomery P, Rivkin SE, Appelbaum FR, Bensinger WI. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22(7):651-659.

Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncology 1998; 16(3):890-896.

LM Bavisotto, C Rankin, BC Behrens, DR Gandara, Rivkin SE, SP Balcerzak, K Antman. A phase II Southwest Oncology Group study of dihydroxyazcytidine for mesothelioma. Cancer Therapeutics 1(1):18-20, 1998

Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Cocca D, Ravdin P, O’Sullivan J, Rivkin SE, Martino S, Osborne CK. bcl 2, p53 and response to tamoxifen in estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group Study. J Clin Oncol 1997; 15(5):1916-1922.

JK Weick, J Crowley, RB Natale, BL Hom, Rivkin SE, CA Coltman Jr, SA Taylor, RB Livingston. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: A Southwest Oncology Group study. Classic Papers and Current Comments 2(1):172-177, 1997.

Rivkin SE, Green S, Metch B, Jewell WR, Constanzi JJ, Altman SJ, Minton JP, O'Bryan RM, Osborne CK. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node positive and estrogen receptor negative patients: A Southwest Oncology Group study. Classic Papers and Current Comments 1996; 1(1):129-135.

Rivkin SE, Green S, Metch B, Cruz AB, Abeloff M D, Jewell WR, Constanzi JJ, Farrar WR, Minton JP, Osborne C K. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node positive and estrogen receptor positive breast cancer patients: A Southwest Oncology Group study. Classic Papers and Current Comments 1996;1(1):120-128.

Rivkin SE. Green S, Metch B, Glucksberg H, Gad el Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK, Vaughn CB. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10 year results of a Southwest Oncology Group study. Classic Papers and Current Comments 1996 1(1):85-93.

Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, Weaver CH, Demirer T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Maziarz R, Klarnet JP, Rivkin SE, Trueblood K, Storb R, Holmberg L, Buckner CD. Phase II study of high dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 943-950.

Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for pre menopausal, node positive, and estrogen receptor positive breast cancer patients: A Southwest Oncology Group study. J Clin Oncol 1996; 14(1):46-51.

Kelly K, Crowley JJ, Bunn PA Jr, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin SE, Livingston R. Role of recombinant interferon alfa 2a maintenance in patients with limited stage small cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. J Clin Oncol 1995;14(1):2924-2930.

Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Solanki D, Cruz AB Jr, Gagliano R, Estes NC, Tangen CM, Rivkin SE. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2(6): 488-494.

Fabian C, Giri S, Estes N, Tangen CM, Poplin E, Vogel S, Goodwin W, Rivkin SE, Fleming R, Macdonald JS. Adjuvant continuous infusion 5-FU, whole abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: A Southwest Oncology Group Pilot study. Int J Radiat Oncol Biol Phys 1995;32(2):457-464.

Petersdorf S, Rivkin SE, Gooley T, et al. Phase I study of high dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994;14(5):813-819.

Rivkin SE, Bensigner W, Hayes FA, Fagnan L, Oien T. Priming with GM CSF prior to high dose CEP chemotherapy for Stage IV cancer. Proc Am Soc Clin Oncol 1995; 14:323 (abst 957).

Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP. Osborne CK. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node positive, and estrogen receptor positive breast cancer patients: A Southwest Oncology Group study [see comments]. J Clin Oncol 1994; 12(10):2078 2085.

Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR. Macdonald JS. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: A Southwest Oncology Group study. Cancer 1994; 73(5):1505-1508.

Rivkin SE, Green S, Metch B, Jewell W R, Costanzi J J, Altman S J, Minton J P, O'Bryan R M, Osborne C K. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node positive and estrogen receptor negative patients: A Southwest Oncology Group study. J Clin Oncol 1993; 11(9): 1710-1716.

Blumenstein B Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr. Doxorubicin, mitomycin-C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study. J Urol 1993; 150(2): 411-413.

Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11(7):1276-1285.

Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer: A Southwest Oncology Group study. Cancer 1993; 71(12):3975-3978.

Harvey WH, Fleming TR, Goodman PJ, Harvey JH, Rivkin SE, MacDonald JS. Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma: A Southwest Oncology Group study (8712). Invest New Drugs 1993; 11(1):45-46.

Albain KS, Green S, LeBlanc M, Rivkin SE, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node positive adjuvant CMFVP breast cancer data base: A pilot study. Breast Cancer Res Treat 1992; 22(3):273-284.

Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, et al. Prognostic significance of progesterone receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10(8):1284-1291.

Sesterhenn I A, Weiss R B, Mostofi F K, Stablein D M, Rowland R G, Falkson G, Rivkin SE, Vogelzang N J. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the Testicular Cancer Intergroup Study. J Clin Oncol 1992; 10(1):69-78.

Higano C S, Goodman P, Craig J B, Kish J A, Rivkin SE, Wolf M, Crawford E D. Phase II evaluation of amonafide in renal cell carcinoma: A Southwest Oncology Group study. Invest New Drugs 1991; 9(4):361-363.

Ellis G K, Green S, Schulman S, Coltman C A Jr, Hynes H E, Rivkin SE, Livingston R B. Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer: A Southwest Oncology Group study. Cancer 1991; 68(5):934-939.

Weick JK, Crowley J, Natale RB, Hom BL, Rivkin SE, Coltman CA Jr, Taylor SA, Livingston RB. A randomized trial of five cisplatin containing treatments in patients with metastatic non small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1991; 9(7):1157-1162.

Silver RT, Case DC Jr, Wheeler RH, Miller TP, Stein RS, Stuart JJ, Peterson BA, Rivkin SE. Golomb HM, Costanzi J, et al. Multicenter clinical trial of mitoxantrone in non Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9(5):754-761.

Goodman GE, Crowley J, Livingston RB, Rivkin SE, Albain K, McCulloch JH. Treatment of limited small cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high dose cyclophosphamide: A Southwest Oncology Group study. J Clin Oncol 1991; 9(3):453-457.

Grever MR, Crowley J, Salmon S, McGee R, Kraut EH, Buys SS, Rivkin SE. Phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group study. J Natl Cancer Inst 1990; 82(22):1778-1779.

Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE. Phase II evaluation of recombinant interferon beta (IFN beta ser) in patients with diffuse mesothelioma: A Southwest Oncology Group study. J Interferon Res 1990; 10(5):531-534.

Guy JT, Fleming T, Pollock TW, Rivkin SE, Pugh RP, Saiers H, Hynes HE, Boyd JF. 5-day vinblastine infusion for pancreatic adenocarcinoma: A Phase II Southwest Oncology Group study. Invest New Drugs 1990; 8(2):205-206.

Rivkin SE, Green S, Metch B, Glucksberg H, Gad el Mawla N, Constanzi J J, Hoogstraten B, Athens J. Maloney T, Osborne C K. et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol 1989; 7(9):1229-1238.

Peters WA 3d, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol 1989; 34(3):323-327.

Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73(1):57-63.

Sause WT, Crowley J, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, Taylor SA, Molnar B. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases: A Southwest Oncology Group study. J Neurooncol 1988; 6(2):107-112.

Cowan JD, Green S, Lucas J, Weick JK, Balcerzak SP, Rivkin SE, Coltman CA, Baker LH. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 1988; 6(3):247-248.

Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, Costanzi JH. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors: A Southwest Oncology Group study. Cancer 1987; 60(12):2891-2895.

Oishi N, Berenberg J, Blumenstein BA, Johnson K, Rivkin SE, Bukowski RM, O'Bryan RM, Stephens RL, Quagliana J, Saiers JH, et al. Teniposide in metastatic renal and bladder cancer: A Southwest Oncology Group study. Cancer Treat Rep 1987; 71(12):1307-1308.

Livingston RB, Griffin BR, Higano CS, Laramore GE, Rivkin SE, Goldberg RS, Schulman SF. Combined treatment with chemotherapy and neutron irradiation for limited non small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1987; 5(11):1716-1724.

Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin SE, Buzdar A, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10(5):387-395.

Baker LH, Frank J, Fine G, Balcerzak SP, Stephens RL, Stuckey WJ, Rivkin SE, Saiki J, Ward JH. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: A randomized comparative trial: A Phase III, Southwest Oncology Group study (7613). J Clin Oncol 1987; 5(6): 851-861.

Poplin E, Fleming T, Leichman L, Seydel HG, Steiger Z, Taylor S, Vance R, Stuckey WJ, Rivkin SE. Combined therapies for squamous cell carcinoma of the esophagus: A Southwest Oncology Group study (SWOG 8037). J Clin Oncol 1987; 5(4):622-628.

Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, Rivkin SE, Coltman CA Jr, Ward JH, Livingston RB. Multimodal therapy for limited small cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide field versus reduced field radiation in partial responders: A Southwest Oncology Group study. J Clin Oncol 1987; 5(4):592 600.

Livingston RB, Schulman S, Griffin BR, Tranum BL, Rivkin SE, Goldberg RS, Fabian CJ, Hammond N, Hynes H. Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. Cancer 1987; 59(7):1249-1254.

Alberts DS, Mason NL, O'Toole RV, Hilgers RD, Rivkin SE, Boutselis JG, Pugh RP, Vaitkevicius VK. Green JB, Oishi N. Doxorubicin cisplatin vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study. Gynecol Oncol 1987; 26(2):193-201.

Budd GT, Fleming TR, Bukowski RM, McCracken JD, Rivkin SE, O'Bryan RM, Balcerzak SP, Macdonald JS. 5-fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A Randomized Comparison: A Southwest Oncology Group study. J Clin Oncol 1987; 5(2):272-277.

Livingston RB, Schulman S, Mira JG, Harker G, Vogel S, Coltman CA Jr, Rivkin SE, Budd G T, Grever MR, Crowley JP. Combined alkylators and multiple site irradiation for extensive small cell lung cancer: A Southwest Oncology Group study. Cancer Treat Rep 1986; 70(12):1395-1401.

Saiki JH, Baker LH, Rivkin SE, Shahbender S, Fletcher WS, Athens JW, Balcerzak SP, Bonnet JD. A useful high dose intermittent schedule of adriamycin and DTIC in the treatment of advanced sarcomas. Cancer 1986; 58(10):2196-2197.

Laufman LR, Green JB, Alberts DS, O'Toole R, Hilgers RD, Young DC, Lin F, Rivkin SE. Chemotherapy of drug resistant ovarian cancer: A Southwest Oncology Group study. J Clin Oncol 1986; 4(9):1374-1379.

Peters WA 3d, Blasko JC, Bagley CM Jr, Rudolph RH, Smith MR, Rivkin SE. Salvage therapy with whole abdominal irradiation in patients with advanced carcinoma of the ovary previously treated by combination chemotherapy. Cancer 1986; 58(4):880-882.

Durie BG, Dixon DO, Carter S, Stephens R, Rivkin SE, Bonnet J, Salmon SE, Dabich L, Files J C, Costanzi JJ. Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1986; 4(8):1227-1237.

Cowan JD, Gehan E, Rivkin SE, Jones SE. Phase II trial of bisantrene in patients with advanced sarcoma: A Southwest Oncology Group study. Cancer Treat Rep 1986; 70(5):685-686.

Stephens RL, Kirby R, Crawford ED, Bukowski R, Rivkin SE, O'Bryan RM. High dose AZQ in renal cancer: A Southwest Oncology Group phase II study. Invest New Drugs 1986; 4(1):57-59.

Osborne CK, Rivkin SE, McDivitt RW, Green S, Stephens RL, Costanzi JJ, O'Bryan R. Adjuvant therapy of breast cancer: A Southwest Oncology Group study. NCI Monogr 1986; (1):71-74.

Rivkin SE, Knight WA 3d, McDivitt R, Cruz T. Foulkes M, Osborne CK, Fabian CJ, Costanzi JJ. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. J Steroid Biochem 1985; 23(6B):1151-1154.

Hilgers RD, Von Hoff DD, Stephens RL, Boutselis JG, Rivkin SE. Mitoxantrone in adenocarcinoma of the endometrium: A Southwest Oncology Group study. Cancer Treat Rep 1985; 69(11):1329-1330.

Rivkin SE, Knight WA 3d, McDivitt R, Cruz T, Foulkes M, Osborne CK, Fabian CJ, Costanzi JJ. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. World J Surg 1985; 9(5):723-727.

Rivkin SE, Glucksberg H, Foulkes M, Osborne CK, Tranum W, Gad el Mawla N, Constanzi J. Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: A comparison of CMFVP versus L-PAM. World J Surg. 1985; 9(5):719-722.

Zidar BL, Baker LH, Rivkin SE, Balcerzak SP, Stephens RL. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: A Southwest Oncology Group study. Cancer Treat Rep 1985;69(9):1035-1036.

Bagley CM Jr, Rudolph RH, Rivkin SE, Yon JL Jr. High dose cisplatin therapy for cancer of the ovary: neurotoxicity [letter]. Ann Intern Med 1985; 102(5):719.

Johnson LP, Rivkin SE. The implanted pump in metastatic colorectal cancer of the liver. Risk versus benefit. Am J Surg 1985; 149(5):595-598.

Inamasu M, Oishi N, Chen T, Legha S, McCracken J, Balcerzak S, Stephens R, O'Bryan R, Rivkin SE. Costanzi JJ, et al. Phase II trial of amsacrine in pancreatic carcinoma: A Southwest Oncology Group study. Cancer Treat Rep 1984; 68(11):1411-1412.

Samson MK, Rivkin SE, Jones SE, Costanzi JJ, LoBuglio AF, Stephens RL, Gehan EA, Cummings GD. Dose response and dose survival advantage for high versus low dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer: A Southwest Oncology Group study. Cancer 1984; 53(5):1029-1035.

Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin SE, Buzdar A, Montague E. Using a database of protocol studies to evaluate therapy: A breast cancer example. Stat Med 1984; 3(4):333-339.

Hilgers RD, Rivkin SE, Von Hoff DD, Alberts DS. Mitoxantrone in epithelial carcinoma of the ovary: A Southwest Oncology Group study. Am J Clin Oncol 1984; 7(5):499-501.

Rivkin SE, Glucksberg H, Foulkes M. Adjuvant therapy of breast cancer: A Southwest Oncology Group experience. Recent Results Cancer Res 1984; 96:166-174.

Bukowski RM, Leichman LP, Rivkin SE. Phase II trial of m AMSA in gallbladder and cholangiocarcinoma: A Southwest Oncology Group study. Eur J Cancer Clin Oncol 1983; 19(6):721-723.

Gagliano R, Levin H, El Bolkainy MN, Wilson HE, Stephens RL, Fletcher WS, Rivkin SE, O'Bryan RM. Coltman CA Jr, Saiki JH, Stuckey WJ, Balducci L, Bonnet JD, Dixon DO.  Adriamycin versus adriamycin plus cis diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma: A Southwest Oncology Group study. Am J Clin Oncol 1983; 6(2):215-218.

Knight WA 3d, Rivkin SE, Glucksberg H, Foulkes MA, Costanzi JJ, Stephens RL, Athens JW, O'Bryan RM. Adjuvant therapy of breast cancer: The Southwest Oncology Group experience. Breast Cancer Res Treat 1983;3 Suppl: S27-33.

Eyre HJ, Quagliana JM, Eltringham JR, Frank J, O'Bryan RM, McDonald B, Rivkin SE. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery: A Southwest Oncology Group Report. J Neurooncol 1983; 1(3):171-177.

Myers JW, Von Hoff DD, Coltman CA Jr, Kuhn JG, Van Echo D, Rivkin SE, Pocelinko R. Phase II evaluation of bisantrene in patients with renal cell carcinoma. Cancer Treat Rep 1982; 66(10):1869-1871.

Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad el Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J, Vaughn C. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: A Southwest Oncology Group study. Cancer 1982; 50(3):423-434.

Ratanatharathorn V, Gad el Mawla N, Wilson HE, Bonnet JD, Rivkin SE, Mass R. Phase II evaluation of maytansine in refractory non Hodgkin's lymphoma: A Southwest Oncology Group study. Cancer Treat Rep 1982; 66(7):1687-1688.

Von Hoff DD, Swenerton KD, Hetanen L, Gafney E, Rivkin SE, Schuchart S, Coltman C A Jr. Long distance transportation of specimens for human tumor cloning. Stem Cells 1982; 2(2):122-128.

Samson MK, Fisher R, Stephens RL, Rivkin SE, Opipari M, Maloney T, Groppe CW. Vinblastine, bleomycin and cis-diamminedichloroplatinum in disseminated testicular cancer: response to treatment and prognostic correlations: A Southwest Oncology Group study. Eur J Cancer 1980; 16(10):1359-1366.

McCracken JD, Ray P, Heilbrun LK, Vaitkevicius VK, Saiki JH, Rivkin SE, Rossof AH, Moore TN. 5-fluorouracil, methyl CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: A Southwest Oncology Group study. Cancer 1980; 46(7):1518-1522.

Rivkin SE, Gottlieb JA, Thigpen T, El Mawla NG, Saiki J, Dixon DO. Methyl CCNU and adriamycin for patients with metastatic sarcomas: A Southwest Oncology Group study. Cancer 1980; 46(3):446-451.

Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS. Bodey GP. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 1980; 64(1):93-98.

ABSTRACTS:

Whitehead RP, McCoy S, MacDonald JS, Rivkin SE, Neubauer MA, Dakhill SR, Lenz HJ, Tanaka MS, Abbruzzese JK. Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer. A Southwest Oncology Group (SWOG) trial. Investigational New Drugs, 24:335-341, 2006.

Influence of Tumor Type, Disease Status, and Patient Age on Self-Reported Interest Regarding Participation in Cancer Clinical Trials. 2006 ASCO Annual Meeting Atlanta, Georgia

Rivkin SE, Markman M, Markman M R, Belland A, Peterson J, Swedish Cancer Institute, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Stanford University, Palo Alto, CA; NexCura, Seattle, WA Profile of Ovarian Cancer Patients Seeking Information from a Proprietary Web-based Decision Support Program.

J Gralow, S Green, D Lew, W Barlow, K Dammann, G Somlo, Rivkin SE, Taylor S, Wong L, Livingston R. SWOG S0102: A Phase II Study of Docetaxel (DOC) and Vinorelbine (VNR) + Filgrastim for HER-2 Negative, Stage IV Breast Cancer. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):20s (#567), 2005

Whitehead RP, McCoy SA, Rivkin SE, Gross HM, Conrad ME, Abbruzzese JL. A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) in Patients with Advanced Pancreas Cancer: A Southwest Oncology Group Study. ASCO Meeting Abstracts Jul 15 2004: 4012.

Rivkin SE, Gown AM, Malmgren JA, Tickman RJ, Atwood M, Iriarte D. Vascular Endothelial Growth Factor Expression and Survival in Node-Positive Breast Cancer Patients Treated with Adjuvant Therapy 2004 Annual ASCO Symposium (abst # 2361) June 2004.

Burris H., Rivkin SE, Ritch P, Mettinger K ; Sarah Cannon. A Randomized Phase III Study of Rubitecan (ORA; Orathecin) vs Best Choice (BC) in 409 Patients with Refractory Pancreatic Cancer-Report from a North-American Mulit-Center Study." CancerCenter, Nashville, TN; Swedish Medical Center, Seattle, WA; Medical College of Wisconsin, East Milwaukee, WI; SuperGen, Inc., Dublin, CA; on behalf of the Orathecin North Amercian Multi-Center Study Group. “ASCO GI Symposium. January 2004

Rivkin SE, Brody JJ, Diel I, Bergstrom B. Long-term Safety of Intravenous Ibandronate by Bolus Injection or Infusion for up to 4 years in Metastatic Bone Disease: Results of an Open-Label Study. Swedish Cancer Institute, Seattle, WA, USA, University Libre de Bruxelles, Brussels, Belgium, CGG-Klinik GmbH, Mannheim, Germany, Hoffmann-LaRoche Inc, New Jersey, USA Poster Presentation at The IVth International Conference on Cancer-Induced Bone Diseases, San Antonio, TX, December 2003

Ellis GK, Green SJ, Livingston RB, Budd GT, Rivkin SE, Giguere JK, Gandara DR, Weiss GR, Martino S, Puget Sound Consortium, Sea. WA., Southwest Oncology Group, Sea. WA., UW Cancer Ctr., Sea. WA., Cleveland Clin Fdn, Cleveland, OH, Greenville CCOP, Greenville, SC, Univ. of CA Davis, Sacramento, CA Univ. of Texas Health Science Ctr, San Antonio, TX, John Wayne Cancer Institute, Santa Monica, CA. Neoadjuvant Doxorubicin, Cyclophosphamide and G-CSF (AC+G) for Locally Advanced Breast cancer (LABC) A Southwest Oncology Group Phase II Study. 2000 (abst 326)

Rivkin SE, Burris H, Gerstein H, Reynolds R, Staddon A, Lenza L, Marinaro JA, Sun SL, Rubitecan Study Group, SuperGen, Inc., San Ramon, CA 2000 ( abst 1020)

Rivkin SE , Green S, Lew D, Glucksberg H, Gad-el-Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, Osborne C, Vaughn C, Martino S. Adjuvant CMFVP versus Melphalan for operable breast cancer with positive axillary nodes: 23-year results of a Southwest Oncology Group study. Pro Am Soc Clin Oncol 1999 (abst 259).

Rivkin SE, Gown A, Tickman R. Parathormone related protein expression in breast cancer patients and its relationship to subsequent bone metastasis. Pro Am Soc Clin Oncol 1998 (abst 656).

Ellis GK, Livingston RB, Lechner J, Feldman E, Petersdorf S, Kalisiak A, Thompson T, Rivkin SE. Adjuvant high dose cyclophosphamide, etoposide and cisplatin (CEP) not requiring stem cell rescue for high risk localized breast cancer. Proc Am Soc Clin Oncol 1995; 14:124 (abst 196).

Livingston R, Collins C, Williams M, Thompson T, Rivkin SE. Determinants of outcome after consolidation for Stage IV breast cancer with cyclophosphamide, etoposide and cisplatin (CEP). Proc Am Soc Clin Oncol 1994; 13:58 (abst 34).

Rivkin SE, Bensinger W, Hayes FA, Fagnan L. Priming with GM CSF prior to high dose CEP chemotherapy. Breast Cancer Symposium, Dec 10, 1994. San Antonio, Texas.

Livingston R, Collins C, Thompson T, Rivkin SE, Levenson R, Senecal F. High dose cyclophosphamide, etoposide, and cisplatin (CEP) consolidation for Stage IV breast cancer. U 1993; 12:62 (abst 50).

Albain K, Rivkin SE, Green S, LeBlanc M, Osborne K. A recursive partitioning and amalgamation (RPA) analysis of the Southwest Oncology Group node+ adjuvant CMFVP data base: four distinct prognostic groups are described by age, ER and number of nodes. Proc Am Soc Clin Oncol 1992; 11:57 (abst 53).

Panettiere FJ, Lehane D, Fletcher WS, Stephens R, Rivkin SE, McCracken JD. Cisplatinum therapy of previously treated head and neck cancer: The Southwest Oncology Group's two dose per month outpatient regimen. Med Pediatr Oncol 1980; 8(3):221-225.

Samson MK, Stephens RL, Rivkin SE, Opipari M, Maloney T, Groppe CW, Fisher R. Vinblastine, bleomycin, and cis dichlorodiammineplatinum(II) in disseminated testicular cancer: preliminary report of A Southwest Oncology Group study. Cancer Treat Rep 1979; 63(9-10):1663-1667.

Alberts DS, Hilgers RD, Moon TE, Martimbeau PW, Rivkin SE. Combination chemotherapy for alkylator resistant ovarian carcinoma: A preliminary report of a Southwest Oncology Group trial. Cancer Treat Rep 1979; 63(2):301-305

Tranum B, Hoogstraten B, Kennedy A, Vaughn CB, Samal B, Thigpen T, Rivkin SE, Smith F, Palmer RL, Costanzi J, Tucker WG, Wilson H, Maloney TR. Adriamycin in combination for the
treatment of breast cancer: A Southwest Oncology Group study. Cancer 1978; 41(6):2078-2083.

Livingston RB, Moore TN, Heilbrun L, Bottomley R. Lehane D, Rivkin SE, Thigpen T. Small cell carcinoma of the lung: combined chemotherapy and radiation: A Southwest Oncology Group study. Ann Intern Med 1978; 88(2):194-199.

O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977 May. 39(5). P 1940 8.

Bearden JD III, Coltman CA Jr, Moon TE, Costanzi JJ, Saiki J H, Balcerzak S P, Rivkin SE, Morrison F S. Lane M, Spigel S C. Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors. Cancer 1977; 39(1):21-26.

Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H. Combination chemotherapy and adriamycin in patients with advanced breast cancer: A Southwest Oncology Group study. Cancer 1976; 38(1):13-20.

Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP Sr, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C Jr, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE. Role of DTIC (NSC 45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60(2):199-203.

Johnson LP, Rivkin SE, Weber EL. Palliation in malignant pleural effusion. Am Surg 1975; 41(9):529-534.

Tranum BL, Haut A, Rivkin SE, Weber E, Quagliana JM. Shaw M, Tucker WG, Smith FE, Samson M, Gottlieb J. A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: A Southwest Oncology Group study. Cancer 1975; 35(4):1148-1153.

Gottlieb JA, Baker LH, Burgess MA, Sinkovics JG, Moon T, Bodey GP, Rodriguez V, Rivkin SE, Saiki J. O'Bryan RM. Sarcoma chemotherapy. In: Cancer Chemotherapy, Year Book Medical Publishers, Chicago, 1975:445-454.

Hoogstraten B, Haas CD, Haut A, Talley RW Rivkin SE, Isaacs BL. CCNU and bleomycin in the treatment of cancer: A Southwest Oncology Group Study. Med Pediatr Oncol 1975; 1(2):95-106.